Table 3.
Treatment outcomes according to the dose intensity
| Clinical outcome | Dose intensity of doxorubicin (mg/m2/wk) |
|||||
|---|---|---|---|---|---|---|
| Age < 70 yr |
Age ≥ 70 yr |
|||||
| ≤ 10 | > 10 | p-value | ≤ 10 | > 10 | p-value | |
| Attainment of CR | ||||||
| No | 4 (44.4) | 59 (17.3) | 0.059 | 4 (40.0) | 26 (35.6) | 1.000 |
| Yes | 5 (55.6) | 282 (82.7) | 6 (60.0) | 47 (64.4) | ||
| Disease progression | ||||||
| No | 3 (33.3) | 268 (78.6) | 0.005 | 4 (40.0) | 48 (65.8) | 0.164 |
| Yes | 6 (66.7) | 73 (21.4) | 6 (60.0) | 25 (34.2) | ||
| Death | ||||||
| No | 4 (44.4) | 272 (79.8) | 0.023 | 2 (20.0) | 35 (47.9) | 0.173 |
| Yes | 5 (55.6) | 69 (20.2) | 8 (80.0) | 38 (52.1) | ||
| 2-Year PFS rate (%) | 55.6 | 82.0 | < 0.001 | 35.0 | 65.7 | 0.036 |
| HR for PFS (95% CI) | 4.043 (1.756-9.305) | 0.001 | 2.520 (1.021-6.224) | 0.045 | ||
| 2-Year OS rate (%) | 66.7 | 84.7 | 0.004 | 40.0 | 62.6 | 0.031 |
| HR for OS (95% CI) | 3.459 (1.394-8.579) | 0.007 | 2.242 (1.036-4.854) | 0.040 | ||
Values are presented as number (%) unless otherwise indicated. CR, complete remission; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival.